Latest Typical antipsychotic Stories
INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today.
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGAÂ® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDALÂ® CONSTAÂ®, according to new data from a comparative study of both treatments in patients with schizophrenia.
WALTHAM, Mass., Dec.
Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.
EAST HANOVER, N.J., Oct.
ROCKVILLE, Md., Oct. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada.
ISTANBUL, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study.
Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS(R) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.
KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S.
Older diabetic patients who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a new report.